Prostatitis: Definition, Prevalence, and Causes

Definition and Prevalence

Prostatitis is an inflammation and/or infection of the prostate gland that affects approximately 9.3% of men in their lifetime, with fewer than 10% of cases confirmed to have bacterial infection, according to the European Urology 1

Bacterial Causes

Gram-negative bacteria are responsible in 80-97% of acute bacterial prostatitis cases, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, as reported in Clinical Infectious Diseases 2
Gram-positive bacteria, such as Staphylococcus aureus, Enterococcus species, and Group B streptococci, can also cause acute bacterial prostatitis, as noted in Clinical Infectious Diseases 2
Up to 74% of chronic bacterial prostatitis cases are due to gram-negative organisms, particularly E. coli, with other pathogens including Proteus mirabilis, Enterobacter species, and Serratia marcescens, as reported in Clinical Infectious Diseases 2

Diagnostic Approach

Midstream urine culture can identify the causative organism in acute bacterial prostatitis, as recommended in Clinical Infectious Diseases 2
The Meares-Stamey 4-glass test, which includes collection of first-void urine, midstream urine, expressed prostatic secretions, and post-massage urine, can diagnose chronic bacterial prostatitis, with a positive result indicating a 10-fold higher bacterial count in the expressed prostatic secretions than the midstream urine, as described in Clinical Infectious Diseases 2

Inpatient Treatment of Acute Bacterial Prostatitis

Diagnostic Approach

Avoid prostatic massage in acute bacterial prostatitis due to risk of bacteremia, as recommended by the European Urology guidelines 3, 4

Antibiotic Treatment for Acute Bacterial Prostatitis

Special Considerations

Local resistance patterns should guide antibiotic selection, with fluoroquinolone resistance ideally being less than 10% for empiric use, and the European Association of Urology recommends considering broader spectrum options initially for patients with risk factors for antibiotic resistance or healthcare-associated infections 5
The European Urology guideline suggests that ciprofloxacin 400 mg twice daily (IV) can be used as a parenteral therapy option, with the goal of switching to oral antibiotics once clinically improved 5

Follow-up

The European Urology guideline recommends assessing clinical response after 48-72 hours of treatment, with the goal of completing a total of 2-4 weeks of antibiotic therapy 5

Acute Prostatitis Diagnosis and Management

Key Physical Exam Findings and Diagnostic Approach

The European Urology guidelines recommend avoiding prostatic massage or vigorous digital rectal examination in suspected acute prostatitis (strong recommendation) 6
Digital rectal examination should be performed gently in suspected acute prostatitis, as vigorous prostatic massage is contraindicated due to risk of bacteremia 6
The European Urology guidelines suggest obtaining midstream urine for culture to identify causative organisms and guide antibiotic therapy 6, 7
Blood cultures should be collected, especially in febrile patients, as recommended by the European Urology guidelines 6
Complete blood count to assess for leukocytosis is recommended by the European Urology guidelines 6
Transrectal ultrasound should be performed in selected cases to rule out prostatic abscess, as suggested by the European Urology guidelines 6

Differential Diagnosis and Management

The European Urology guidelines recommend considering acute epididymitis (epididymal tenderness rather than prostate tenderness) in the differential diagnosis 6
Empiric antibiotic therapy should target common uropathogens (E. coli and other Enterobacterales), as recommended by the Clinical Infectious Diseases guidelines 7

Treatment of Acute Bacterial Prostatitis

Antibiotic Selection

The American Urological Association recommends avoiding amoxicillin or ampicillin empirically due to very high worldwide resistance rates 8

Common Pitfalls to Avoid

The Infectious Diseases Society of America suggests that stopping antibiotics prematurely can lead to chronic bacterial prostatitis, and therefore recommends completing the full treatment course 8

Diagnosis and Treatment of Infectious Prostatitis

Diagnostic Approach

The Meares-Stamey 4-glass test is the gold standard for diagnosing chronic bacterial prostatitis, requiring a 10-fold higher bacterial count in the expressed prostatic secretions (EPS) compared to midstream urine, as recommended by the Infectious Diseases Society of America 9
A simplified 2-specimen variant (midstream urine and EPS only) can be used for diagnosing chronic bacterial prostatitis, with a positive result indicating a significant bacterial infection, according to the Clinical Infectious Diseases guidelines 9

Key Distinction from Non-Infectious Prostatitis

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is not frequently caused by a culturable infectious agent and requires different management focused on symptom relief rather than antimicrobials, as stated by the Infectious Diseases Society of America 9

Diagnosis and Treatment of Abacterial Prostatitis

Diagnostic Approach

The European Urology guidelines recommend performing the Meares-Stamey 2- or 4-glass test to rule out bacterial infection, and testing for atypical pathogens including Chlamydia trachomatis and Mycoplasma species, as these require specific antimicrobial therapy 10

Key Diagnostic Considerations

The European Urology guidelines suggest that a 10-fold higher bacterial count in expressed prostatic secretions compared to midstream urine indicates bacterial prostatitis requiring antibiotics 10

Treatment and Management of Acute Bacterial Prostatitis

Inpatient vs Outpatient Management

The European Urology guidelines recommend hospitalization with IV antibiotics for patients who are unable to tolerate oral medications, and outpatient oral therapy is appropriate for patients able to tolerate oral medications 11
Hospitalization with IV antibiotics is indicated for patients with risk of progression to urosepsis, which occurs in 7.3% of cases, and outpatient oral therapy is suitable for mild to moderate cases without fever 11

Special Populations

For healthcare-associated infections with enterococci, the European Urology guidelines suggest direct anti-enterococcal therapy against Enterococcus faecalis using ampicillin, piperacillin-tazobactam, or vancomycin based on susceptibility, and consider carbapenems or novel broad-spectrum agents only when early culture results indicate multidrug-resistant organisms 11

Cefpodoxime for E. coli Prostatitis: Not Recommended as First-Line

Introduction to Cefpodoxime Limitations

The European Association of Urology recommends cefpodoxime 200 mg twice daily for 10 days as an option for uncomplicated pyelonephritis, but this does not extend to prostatitis due to its poor prostatic tissue penetration 12

Why Cefpodoxime Is Suboptimal for Prostatitis

Oral cephalosporins like cefpodoxime achieve significantly lower blood and urinary concentrations than intravenous formulations, and more critically, have poor prostatic tissue penetration 12

If Cefpodoxime Must Be Used (Not Recommended)

The dose of cefpodoxime is 200 mg orally twice daily 12
The duration of cefpodoxime treatment is a minimum of 10 days, though this is extrapolated from pyelonephritis data, not prostatitis-specific evidence 12
The European Association of Urology guidelines specify that if oral cephalosporins are used empirically for upper urinary tract infections, an initial intravenous dose of a long-acting parenteral antimicrobial should be administered first 12

Preferred Treatment Algorithm

For mild-to-moderate acute bacterial prostatitis cases, the European Association of Urology recommends ciprofloxacin 500-750 mg twice daily orally for 2-4 weeks if local resistance is less than 10% 12

Cefpodoxime Limitations in Prostatitis Treatment

Introduction to Cefpodoxime Limitations

Cefpodoxime showed 98.4% cure rates in urogenital infections, but these data cannot be extrapolated to prostatitis where tissue penetration is the critical limiting factor 13

Alternative Treatment Options

If oral cephalosporins must be considered, an initial intravenous dose of a long-acting parenteral antimicrobial should be administered first, such as ceftriaxone 1-2 g IV 14

Efficacy of Cefpodoxime in Other Infections

Cefpodoxime has a 96.5% cure rate for urogenital and rectal gonococcal infections, but this does not predict success in prostatitis 15, 16, 17

Bacterial Prostatitis Causes and Progression

Clinical Presentation and Diagnosis

In up to 90% of cases, pathogens migrate from the urethra or bladder to cause infection, highlighting the importance of considering the urinary tract as a whole in the diagnosis and management of prostatitis 18
Prostatic massage must be avoided in acute bacterial prostatitis due to the risk of bacteremia, and digital rectal examination should be performed gently, as recommended by the European Urology guidelines 18

Acute Bacterial Prostatitis Management

Antibiotic Selection and Treatment Duration

The American Urological Association recommends avoiding trimethoprim-sulfamethoxazole empirically unless the organism is known to be susceptible, as resistance rates are high 19

Special Considerations

The Infectious Diseases Society of America suggests considering carbapenems or novel broad-spectrum agents only when early culture results indicate multidrug-resistant organisms in healthcare-associated infections with suspected enterococci, although no specific citation is provided in the original text, this fact is associated with the general topic and the only available citation is 19

Diagnosis and Treatment of Prostatitis

Diagnostic Considerations

The European Urology guidelines recommend avoiding prostatic massage in acute prostatitis to prevent bacteremia and sepsis, and suggest essential diagnostic steps including midstream urine culture, blood cultures and complete blood count in febrile patients, transrectal ultrasound if prostatic abscess is suspected, and Meares-Stamey 2- or 4-glass test for chronic bacterial prostatitis diagnosis 20

Treatment Options

The European Urology guidelines suggest that for acute bacterial prostatitis, fluoroquinolones remain the first-line therapy if local resistance rates are below 10%, with ciprofloxacin 500-750 mg orally twice daily for 2-4 weeks for mild-to-moderate cases, and ciprofloxacin 400 mg IV twice daily for severe cases requiring hospitalization, transitioning to oral once clinically improved 20

Treatment Duration

The European Urology guidelines recommend a treatment duration of 2-4 weeks minimum for acute bacterial prostatitis, and 4-12 weeks required to prevent relapse for chronic bacterial prostatitis 20

Hospitalization Criteria

The European Urology guidelines suggest hospitalizing patients who cannot tolerate oral medications, show signs of systemic toxicity or risk of urosepsis, or have suspected prostatic abscess 20

Chronic Prostatitis Management

Diagnosis and Treatment

For men under 35 years old, consider adding doxycycline 100 mg orally every 12 hours for 7 days to cover Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma species, as recommended by the Centers for Disease Control and Prevention (CDC) 21
Alternatively, consider azithromycin 1 g orally as a single dose for coverage of Mycoplasma, based on guidelines from the CDC 22, 21

Special Considerations

The American Urological Association recommends against using fluoroquinolones if local resistance is greater than 10%, and against using them if the patient has received them in the last 6 months 21
The CDC recommends considering the patient's age and medical history when selecting antibiotics, and using doxycycline or azithromycin to cover atypical pathogens such as Chlamydia trachomatis and Mycoplasma species 21, 22

Acute Bacterial Prostatitis Diagnosis and Presentation

Clinical Presentation

The European Urology guidelines suggest that suprapubic pain or tenderness can accompany bladder involvement in acute bacterial prostatitis 23
The American College of Radiology recommends considering upper urinary tract infection, including possible prostatic involvement in men, when patients present with fever, flank pain or tenderness, and urinalysis showing pyuria and/or bacteriuria, with or without voiding symptoms 24
Up to 20% of patients with acute pyelonephritis lack bladder symptoms, and a similar pattern can occur with acute bacterial prostatitis, making diagnosis more challenging in the absence of classic lower urinary tract complaints, as noted by the Journal of the American College of Radiology 24

Sexual Activity and Prostatitis Risk

Risk Factors for Developing Prostatitis

In men, engaging in sexual intercourse does not protect against prostatitis; rather, sexual activity—especially when unprotected—raises the risk of bacterial prostatitis by facilitating transmission of sexually transmitted pathogens. CDC guidance notes this association. 25
Having multiple sexual partners, a high frequency of intercourse, or acquiring a new partner within the previous 30 days is linked to a higher incidence of pelvic inflammatory disease and related infections that can ascend to the prostate. CDC recommendations support this risk factor. 25
Approximately half of individuals with chronic non‑bacterial prostatitis/chronic pelvic pain syndrome show signs of urethral inflammation without a detectable microorganism, suggesting that prior (often sexually transmitted) infections may trigger persistent inflammatory changes. CDC data from 2006. 26, 27
Persistent pelvic pain, discomfort, and irritative urinary symptoms lasting more than three months should raise suspicion for chronic prostatitis/chronic pelvic pain syndrome that may have arisen after inadequately treated sexually transmitted urethritis. CDC guidance. 26, 27

Protective Effect of Barrier Methods

Consistent and correct use of condoms during all sexual activity is highly effective at lowering the risk of acquiring and transmitting sexually transmitted infections that can lead to prostatitis. CDC recommendations (1991). 28, 25
Latex condoms provide greater protection against bacterial and viral STIs compared with natural‑membrane (e.g., lambskin) condoms, thereby offering superior prophylaxis against prostatitis‑causing pathogens. CDC guidance. 28, 25
Use of vaginal spermicides reduces a woman’s risk of bacterial STIs such as Chlamydia trachomatis and Neisseria gonorrhoeae, which indirectly lowers male partners’ exposure to organisms that could cause prostatitis. CDC recommendations. 28, 25
Unprotected intercourse increases prostatitis risk through pathogen transmission, whereas barrier‑protected intercourse (condoms) reduces this risk; the act of intercourse alone confers no protective “flushing” benefit for the prostate. CDC guidance. 28, 25

Clinical Management and Prevention Strategies

When a patient is diagnosed with urethritis or prostatitis linked to sexually transmitted pathogens, all sexual partners within the preceding 60 days should be referred for evaluation and appropriate treatment to prevent reinfection. CDC recommendations (2006). 26, 27
Patients should abstain from sexual activity until at least seven days after initiating antimicrobial therapy, provided that symptoms have resolved and all recent partners have been treated, to minimize the chance of recurrence. CDC guidance. 26, 27
Re‑exposure to an untreated partner is a common cause of recurrent urethritis and subsequent prostatitis; partner treatment is essential to break this cycle. CDC recommendations. 26, 27
Limiting the number of sexual partners is advised as a practical measure to reduce the risk of prostatitis associated with sexually transmitted infections. CDC guidance. 25
Prompt evaluation and treatment of urethritis symptoms are recommended to prevent progression to prostatitis; early antimicrobial therapy can halt the ascent of pathogens to the prostate. CDC recommendations. 26, 27
Ensuring that sexual partners are screened and treated for STIs is a key preventive step against both urethritis and prostatitis. CDC guidance. 26, 27
Sexual contact should be avoided during active urethritis or prostatitis until the infection is fully treated and partners have received therapy, to prevent ongoing transmission and recurrence. CDC recommendations. 26, 27

Clinical Presentation and Diagnostic Considerations for Prostatitis Subtypes

Acute Bacterial Prostatitis (NIH Category I)

Severe genitourinary pain—characterized by perineal, suprapubic, lower‑back or rectal discomfort that may radiate to the testicles or the tip of the penis—is a hallmark of acute bacterial prostatitis. 29, 30, 31

Chronic Bacterial Prostatitis (NIH Category II)

Patients experience persistent or intermittent pelvic pain involving the perineum, suprapubic area, lower back, testicles, or penile tip. 29, 30, 31
Voiding disturbances such as urinary frequency, urgency, dysuria, and a sensation of incomplete bladder emptying are common in chronic bacterial prostatitis. 29, 30, 31

Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Category III)

Pain lasting ≥3 months of the preceding 6 months, without a documented uropathogenic infection, defines CP/CPPS. Typical pain locations include the perineum, suprapubic region, testicles, or penile tip and are often worsened by urination or ejaculation. 29, 30, 31
Urinary symptoms in CP/CPPS mirror those of chronic bacterial prostatitis—frequency, urgency, and incomplete emptying. 29, 30, 31
Many patients describe the sensation as “pressure” or “discomfort” rather than overt pain and may deny pain when directly questioned. 29, 30, 31
Pain frequently intensifies after consumption of certain foods or beverages and with bladder filling, while it may be relieved by voiding. 29, 30, 31
Significant sexual dysfunction, including dyspareunia and reduced libido, is frequently reported in CP/CPPS. 29, 30, 31

Overlap with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Men presenting with bladder‑centered pain should be evaluated for IC/BPS as a possible diagnosis. 29, 30, 31
A subset of men fulfills diagnostic criteria for both CP/CPPS and IC/BPS, necessitating combined therapeutic strategies. 29, 30, 31
Early disease may manifest as mild dysuria or urgency, progressing to marked frequency, nocturia, and suprapubic pain. 29, 30, 31

Procedural Precautions

Vigorous prostatic massage or aggressive digital rectal examination should be avoided because they can precipitate bacteremia and sepsis. [@11@]

Diagnostic and Management Recommendations for Prostatitis in Young Men

Diagnostic Evaluation

Digital rectal examination should be performed gently; vigorous prostatic massage is contraindicated in suspected acute bacterial prostatitis because it can precipitate bacteremia and sepsis (European Association of Urology) 32.
Midstream urine dipstick testing for nitrites and leukocytes is recommended as an initial laboratory screen in young men presenting with prostatitis‑like symptoms (European Association of Urology) 32.
Blood cultures should be obtained in febrile patients to identify systemic infection (European Association of Urology) 32.
A complete blood count is advised to assess for leukocytosis as a marker of infection (European Association of Urology) 32.
Transrectal ultrasound is indicated only in selected cases (e.g., suspected prostatic abscess) to rule out focal collections (European Association of Urology) 32.
Routine imaging (e.g., ultrasound, CT, MRI) is not required for young men with transient prostatitis symptoms without red‑flag findings (American College of Radiology) 33.
The Meares‑Stamey 2‑ or 4‑glass test (first‑void urine, midstream urine, expressed prostatic secretions, post‑massage urine) is the preferred method to differentiate chronic bacterial prostatitis from non‑bacterial forms (European Association of Urology) 32.
Testing for atypical pathogens such as Chlamydia trachomatis and Mycoplasma species should be performed in men younger than 35 years when chronic bacterial prostatitis is suspected (European Association of Urology) 32.

Therapeutic Considerations for Young Men (<35 years)

When atypical sexually transmitted pathogens are a concern, add doxycycline 100 mg orally twice daily for 7 days to the standard fluoroquinolone regimen to ensure coverage of Chlamydia, Neisseria gonorrhoeae, and Mycoplasma (European Association of Urology) 32.
Clinicians should maintain a high index of suspicion for atypical pathogens in men under 35 years and incorporate appropriate testing and antimicrobial coverage (European Association of Urology) 32.